Navigation Links
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
Date:6/25/2009

y few studies have examined the extent of the pharmacokinetic (PK) and pharmacodynamic (PD) interaction between them, particularly when taken at therapeutic doses. A literature review was conducted to gather published data on the safety risks associated with alcohol-opioid interactions, alcohol-induced dose-dumping, and the methodology used to characterize such interactions. The review found that the combination of EtOH and select opioids at the studied doses does not appear to produce additive pharmacodynamic effects, while the pharmacokinetic profiles may be affected for certain other opioids when combined with EtOH. Additional studies would be required to further assess and verify these findings

About ACUROX(R) Tablets

ACUROX(R) is an investigational patented, orally administered, immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient with a proposed indication for the relief of moderate- to-severe pain. ACUROX(R) utilizes Acura's proprietary Aversion(R) Technology. Aversion(R) Technology is a patented triple-action composition of niacin and inactive ingredients. These ingredients can generate a temporary, unpleasant effect if orally over-consumed, turn dissolved tablets into a thick gelatinous mixture making it difficult to draw into a syringe, or produce a mild burning sensation in the nostrils when crushed and snorted. There is no evidence that ACUROX(R)'s triple-action combination of niacin and inactive ingredients reduces its abuse liability.

About EMBEDA(TM)

EMBEDA(TM) is an investigational long-acting opioid analgesic that contains extended-release morphine pellets, each with a sequestered core of naltrexone, an opioid antagonist. The formulation is designed to work such that if taken as directed, the morphine would relieve pain while the sequestered naltrexone would pass through the body with no intended clinical effect. If EMBEDA(TM) is crushed
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... LA JOLLA, Calif. , Nov. 26, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery and development ... Kleanthis G. Xanthopoulos , Ph.D., President and CEO of ... th Annual Piper Jaffray Healthcare Conference at the ... at 2:00 p.m. EST.  The presentation will be webcast ...
(Date:11/26/2014)... Scott Steiger lives in St. Louis ... for the past 20 years, he,s traveled extensively and prior to ... to six of the seven continents. Travel is a big part ... Photo - http://photos.prnewswire.com/prnh/20141126/161077 So when he ... idea of what,s required. His latest creation is the ...
(Date:11/26/2014)... -- CARsgen, a leader in the development of Chimeric Antigen ... of cancers, today announced the completion of a series ... -based healthcare private equity fund.   ... of new therapeutics for liver, lung, stomach and brain ... Renji Hospital, the company plans to initiate clinical studies ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2CARsgen Completes Series A Financing 2
... Dermatologist Promoting Regular Skin Examinations, SAN DIEGO, ... resident is diagnosed with a new case of ... A local dermatologist is working,to decrease this alarming ... with this deadliest type of skin cancer will ...
... treatment of Gaucher Disease, CARMIEL, Israel, Aug. 27 ... that it has treated the,first patient in its phase ... a proprietary plant cell expressed recombinant form of,human Glucocerebrosidase ... disorder in humans. The phase III clinical trial ...
Cached Medicine Technology:Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment 2Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD 2Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD 3
(Date:11/27/2014)... Two international trainers and lecturers on the ... one person with significant needs but limited means obtain ... Mamaly Reshad of the Anacapa Dental Art Institute in ... devoted to helping dentist learn about using All-on-4™ dental ... devoted to helping a patient who has damaged or ...
(Date:11/27/2014)... “LAB.C” was featured on NewsWatch as part ... coolest technology products available to consumers. Mallory Sofastaii, a technology ... and shared with viewers the company offers a cable ... , Consumers love portability and functionality. A unique mobile ... the iPhone5 and 5S has a portable USB charger built ...
(Date:11/27/2014)... Texas (PRWEB) November 27, 2014 ... report on Global Insulin industry. For an overview ... definition, classification, application, industry chain structure, industry overview, ... on global Insulin industry covers information on ... process, product cost structure and much more. ...
(Date:11/27/2014)... 27, 2014 Allowing children to help with ... school, helps give children responsibility, ownership, boosts self-esteem, and above ... , Now, the real question is, how do you encourage ... According to a study published by Child Development Journal, there ... dramatic effect on a child’s willingness to lend a hand. ...
(Date:11/27/2014)... 27, 2014 RBSEO Services, a ... engine optimization service just at $99. RBSEO Services ... cannot afford costly search engine optimization service. So, ... their affordablity and requirements into consideration. , ... it has not compromised with the service quality. ...
Breaking Medicine News(10 mins):Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:RBSEO Services Announces SEO Services at $99 Only 2
... McClellan to Give Keynote Speech, WASHINGTON, June ... molecular machinery is pointing toward new drugs and,treatments ... emerging,era of health care, called personalized medicine, also ... and industry,marketing strategies., To help the food ...
... New West,s Ability to Provide Outstanding ... Healthcare Service and Access, ... PER ) and New West Health Services -- Montana,s second,largest ... Systems will host New West,s enterprise core administrative,system (CAS), and ...
... (St. Mary,s City, MD) June 12, 2008Encore Creativity for ... will co-host Encore,s first Summer Chorale Camp Tuesday, June ... executive director Jeanne Kelly helped lead a study about ... between regular artistic activity and improved physical and mental ...
... Ovarian function can be preserved and disease activity controlled ... treated with a 6-month course of cyclophosphamide (CYC), a ... according to a new study presented today at EULAR ... Rheumatism in Paris, France. , SLE, a complex ...
... Standards and Technology (NIST) have developed a simplified, ... for biological research. By using a laboratory microwave ... used nanomaterials, the recently published* NIST process avoids ... making quantum dots, resulting in brighter, more stable ...
... a stroke, even unaffected areas of the brain are at ... dead tissue and spread through the adjacent areas of the ... has previously been observed only in animal studies. , A ... along with the Max Planck Institute of Neurological Research in ...
Cached Medicine News:Health News:FDLI, AAAS Host June 20 Conference on Personalized Medicine 2Health News:FDLI, AAAS Host June 20 Conference on Personalized Medicine 3Health News:New West Health Services Selects Perot Systems Xcelys(TM) 5.0 Software 2Health News:New West Health Services Selects Perot Systems Xcelys(TM) 5.0 Software 3Health News:NIH study concludes next week's summer chorus camp for seniors improves quality of life 2Health News:Ovarian function and fertility preserved in women with severe systemic lupus erythematosus 2Health News:Microwave synthesis connects with the (quantum) dots 2Health News:Tsunami in the brain 2Health News:Tsunami in the brain 3
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
... is our top-of-the-line device. The ... of the Qwik-Let® Elite, in ... feature. The Lan-X technology allows ... in the removal and disposal ...
... The new Finnpipette Focus from Thermo ... with uncompromising performance. Advanced features such ... .01ul fine volume adjustment on microvolumes help ... in single channel pipettes. The new interchangeable ...
... Digital offers improved ergonomics for today's ... modified grippy finger rest and the ... and efficiency. Finnpipette Digitals also feature ... mechanism (pat. pend.) and super blow-out ...
Medicine Products: